References
- 1. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nature Clinical Practice Oncology. 2006;3:152-154.10.1038/ncponc0451
- 2. Nagy J, Kiss I. Az eritropoetin pleiotrop hatásai. LAM. 2007;17(12):861-867.
- 3. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron defi ciency and the specifi c role of i.v. iron. Annals of Oncology. 2012;23:1954-1962.10.1093/annonc/mds112
- 4. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007303. DOI: 10.1002/14651858.CD007303.pub2.10.1002/14651858.CD007303.pub2
- 5. Barrett-Lee PJ, Ludwig H, Birgegård G. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anemia Survey. Oncology. 2006;70:34-48.10.1159/000091675
- 6. Birgegård G, Aapro MS, Bokemeyer C. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68(Suppl 1): 3-11.10.1159/000083128
- 7. Thomas ML. Impact of anemia and fatigue on quality of life in cancer patients; A brief review. Med Oncol. 1998;15:53-57.
- 8. Shasha D, George MJ, Harrison LB. Once weekly dosing of epoetin increases hemoglobin and quality of life in anemic cancer patient receiving radiation therapy either concomitently or sequentially with chemoterapy. Cancer. 2003;98:1072-1079.10.1002/cncr.11616
- 9. Miller Carole B, Jones RJ, Piantados S, Abeloff MD, Spivak JL. Decreased Erythropoietin Response in Patients with the Anemia of Cancer, M.D. N Engl J Med. 1990;322:1689-1692.
- 10. Engert A, Josting A, Haverkamp H, et al. Epoetin Alfa in Patients With Advenced-Stage Hodgkin’s Lymphoma. Results of the Randomized Placebo- Controled GHSG, HD15 EPO Trial. J Clin Oncol. 2010;28(13):2239-2245.10.1200/JCO.2009.25.1835
- 11. Spivak JL, Gascon P, Ludwig H. Anemia Management in Oncology and Hematology. The Oncologist. 2009;14(S1):43-56.10.1634/theoncologist.2009-S1-43
- 12. Coiffi er B. Anemia associated with non-platinum chemotherapy (CT) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL). European Journal of Cancer. 1999;35:S331.10.1016/S0959-8049(99)81747-X
- 13. Campos MPO, Hassan BJ, Riechelmann R, Del Giglio A. Cancer-related fatigue: a practical review. AnnOncol. 2011;22(6):1273-1279.10.1093/annonc/mdq45821325448
- 14. Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematological Oncology. 2001;19(1):19-30.10.1002/hon.66311276043
- 15. Truong Pauline T, Parhar Tarnjit BS, Hart J, Alexander Cheryl, Wai Elaine S. Population-Based Analysis of the Frequency of Anemia and its Management Before and During Chemotherapy in Patients With Malignant Lymphoma. American Journal of Clinical Oncology. 2010;33(5):465-468.10.1097/COC.0b013e3181b4b14719935386
- 16. Pirker R. Safety considerations for erythropoietin treatment in patients with cancer, Expert Opinion on Drug Safety. 2007;6(1):63-69.
- 17. Deger M, Eisterer W, Kutikova Lucie, Salek S. Hemoglobin level at initiation of darbopoetin alfa: impact on need for transfusion and associated costs in chemoterapy-induced anemia treatment in Europe. Supportive Care in Cancer. 2013;21:485-493.10.1007/s00520-012-1538-0353802222825456
- 18. Schrijvers D, Samblanx H, Roila F. Erythropoiesis stimulating agents in the treatment of cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol. 2010;21(Suppl 5):244-247.10.1093/annonc/mdq20220555090
- 19. Carson JL, Grossmann BJ, Kleinmann S, et al. Red blood cell transfusion: a clinical practice guaidline from the AABB. Ann Intern Med. 2012;157: 49-58.10.7326/0003-4819-157-1-201206190-0042922751760
- 20. Eisterer W, Hussl C, Erb H, et al. Evaluating the transfusion rate with darbepoetin alfa 500 microg every 3 weeks in anemic cancer patients receiving chemotherapy. Cur Med Res Opin. 2011;27:355-363.10.1185/03007995.2010.54213421166611
- 21. Canon JL, Vansteenkiste J, Hedenus M, et al. Transfusion risk in cancer patients with chemoterapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobine level of <9 /g/dL versus 9 to 10g/ dL versus ≥ 10g/dL: an exploratory analysis of a phase 3 trial. Med Oncol. 2011, doi: 10.1007/s12032-011-0103-x. 10.1007/s12032-011-0103-x22081263